RECRUITINGINTERVENTIONAL
Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial
SBI 2024-2026 STENO FOOD CONCEPT
About This Trial
This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease (eGFR 30-59 ml/min).
Who May Be Eligible (Plain English)
Who May Qualify:
- Type 2 diabetes (ICD-10 DE11.x)
- Age 18-74 years
- BMI \< 35 kg/m²
- eGFR 30-59 ml/min and UACR \> 30 mg/g
- Stable medication for ≥3 months
- Ability to read and understand Danish
Who Should NOT Join This Trial:
- Type 1 diabetes or other diabetes types
- Current vegan diet
- Active cancer
- Short bowel syndrome or celiac disease
- Use of sodium chloride tablets
- No access to digital platform (intervention group only)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Type 2 diabetes (ICD-10 DE11.x)
* Age 18-74 years
* BMI \< 35 kg/m²
* eGFR 30-59 ml/min and UACR \> 30 mg/g
* Stable medication for ≥3 months
* Ability to read and understand Danish
Exclusion Criteria:
* Type 1 diabetes or other diabetes types
* Current vegan diet
* Active cancer
* Short bowel syndrome or celiac disease
* Use of sodium chloride tablets
* No access to digital platform (intervention group only)
Treatments Being Tested
DEVICE
StenoFood App
Digital patient education program (app-based) with dietary guidance and self-monitoring tools
Locations (2)
Steno Diabetes Center Copenhagen,
Herlev, Captial Region of Denmark, Denmark
Nordsjællands Hospital, Hillerød
Hillerød, Captial Region of Denmark, Denmark